Longeveron Inc. (LGVN)

$ 6.58
-0.74 (-10.11%)
-
Symbol LGVN
Price $ 6.58
Beta 0.000
Volume Avg. 13.29M
Market Cap 0.137B
Shares () -
52 Week Range 2.84-45.0
1y Target Est -
DCF Unlevered LGVN DCF ->
DCF Levered LGVN LDCF ->
ROE -75.82% Strong Sell
ROA -35.81% Strong Sell
Operating Margin -
Debt / Equity 21.12% Neutral
P/E -
P/B 5.07 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest LGVN news


Dr. Joshua Michael Hare
Healthcare
Biotechnology
Nasdaq Global Select

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.